Therapeutic Targeting of Hyaluronan in the Tumor Stroma
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The tumor stroma, consisting of non-malignant cells and the extracellular matrix, undergoes significant quantitative and qualitative changes throughout malignant transformation and tumor progression. With increasing recognition of the role of the tumor microenvironment in disease progression, stromal components of the tumor have become attractive targets for therapeutic intervention. Stromal accumulation of the glycosaminoglycan hyaluronan occurs in many tumor types and is frequently associated with a negative disease prognosis. Hyaluronan interacts with other extracellular molecules as well as cellular receptors to form a complex interaction network influencing physicochemical properties, signal transduction, and biological behavior of cancer cells. In preclinical animal models, enzymatic removal of hyaluronan is associated with remodeling of the tumor stroma, reduction of tumor interstitial fluid pressure, expansion of tumor blood vessels and facilitated delivery of chemotherapy. This leads to inhibition of tumor growth and increased survival. Current evidence shows that abnormal accumulation of hyaluronan may be an important stromal target for cancer therapy. In this review we highlight the role of hyaluronan and hyaluronan-mediated interactions in cancer, and discuss historical and recent data on hyaluronidase-based therapies and the effect of hyaluronan removal on tumor growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 8×
“In preclinical models, removal of HA also leads to normalized tIFP, decompression of vasculature, more efficient drug delivery, and increased survival [11,12,14].”
BackgroundMethodInfluentialHyaluronan: from extracellular glue to pericellular cue
Toole, B. P. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1391 · Cited by 2,125
Regulation of lung injury and repair by Toll-like receptors and hyaluronan
Jiang, D., Liang, J., Fan, J., Yu, S., Chen, S., Luo, Y., Prestwich, G. D., Mascarenhas, M. M., Garg, H. G., Quinn, D. A., et al. (2005) · Nature Medicine · doi:10.1038/nm1315 · Cited by 1,401
Oligosaccharides of Hyaluronan Activate Dendritic Cells via Toll-like Receptor 4
Termeer, C., Benedix, F., Sleeman, J., Fieber, C., Voith, U., Ahrens, T., Miyake, K., Freudenberg, M., Galanos, C., & Simon, J. C. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20001858 · Cited by 1,378
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., Zecchini, H. I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302529 · Cited by 1,120
Self-citationHyaluronan as an Immune Regulator in Human Diseases
Jiang, D., Liang, J., & Noble, P. W. (2011) · Physiological Reviews · doi:10.1152/physrev.00052.2009 · Cited by 1,060
Camenisch, T. D., Spicer, A. P., Brehm-Gibson, T., Biesterfeldt, J., Augustine, M. L., Calabro, A., Kubalak, S., Klewer, S. E., & McDonald, J. A. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10272 · Cited by 901 · cited 2×
“whereas the other synthases may play more subtle roles in development [23,24].”
BackgroundThree isoforms of mammalian hyaluronan synthases have distinct enzymatic properties
Itano, N., Sawai, T., Yoshida, M., Lenas, P., Yamada, Y., Imagawa, M., Shinomura, T., Hamaguchi, M., Yoshida, Y., Ohnuki, Y., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.35.25085 · Cited by 901 · cited 1×
“The three isoforms are independently regulated and are thought to produce distinct molecular weight forms of HA [18–22].”
BackgroundMechanical compression drives cancer cells toward invasive phenotype
Tse, J. M., Cheng, G., Tyrrell, J. A., Wilcox-Adelman, S. A., Boucher, Y., Jain, R. K., & Munn, L. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118910109 · Cited by 631 · cited 1×
“is [48].”
Frost, G. I. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.4.427 · Cited by 323 · cited 1×
“dispersion of co-injected drugs, and is currently being tested in clinical trials to facilitate the subcutaneous delivery of macromolecules [37–39].”
MethodSelf-citationEnzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models
Thompson, C. B., Shepard, H. M., O'Connor, P. M., Kadhim, S., Jiang, P., Osgood, R. J., Bookbinder, L. H., Li, X., Sugarman, B. J., Connor, R. J., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0470 · Cited by 298
Self-citationA recombinant human enzyme for enhanced interstitial transport of therapeutics
Bookbinder, L. H., Hofer, A., Haller, M. F., Zepeda, M. L., Keller, G.-A., Lim, J. E., Edgington, T. S., Shepard, H. M., Patton, J. S., & Frost, G. I. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.05.027 · Cited by 282
Self-citationAspberg, A., Miura, R., Bourdoulous, S., Shimonaka, M., Heinegård, D., Schachner, M., Ruoslahti, E., & Yamaguchi, Y. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.19.10116 · Cited by 275
Eikenes, L., Tari, M., Tufto, I., Bruland, Ø. S., & de Lange Davies, C. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602626 · Cited by 221 · cited 1×
“In addition, previous preclinical studies [106–108] have attributed chemopotentiation by hyaluronidase to a reduction in tIFP, which facilitates enhanced drug penetration into HA-depleted tumors.”
BackgroundLiu, Q., Sun, J. D., Wang, J., Ahluwalia, D., Baker, A. F., Cranmer, L. D., Ferraro, D., Wang, Y., Duan, J.-X., Ammons, W. S., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1852-8 · Cited by 113 · cited 1×
“pancreatic adenocarcinoma (PDA) [8]; and TH-302, a hypoxia-activated prodrug which has also been shown to increase the antitumor activity of a broad range of conventional chemotherapy agents in human xenograft models and for which clinical testing is ongoing [9,10].”
Background
Cited by
Physiochemical properties and application of hyaluronic acid: a systematic review
Salwowska, N. M., Bebenek, K. A., Żądło, D. A., & Wcisło‐Dziadecka, D. L. (2016) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.12237 · Cited by 345
Emerging roles of ECM remodeling processes in cancer
Mohan, V., Das, A., & Sagi, I. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.004 · Cited by 334
Rahbari, N. N., Kedrin, D., Incio, J., Liu, H., Ho, W. W., Nia, H. T., Edrich, C. M., Jung, K., Daubriac, J., Chen, I., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf5219 · Cited by 258
ECM-targeting bacteria enhance chemotherapeutic drug efficacy by lowering IFP in tumor mouse models
Kim, J.-S., Park, J.-E., Choi, S.-H., Kang, S. W., Lee, J. H., Lee, J.-S., Shin, M., & Park, S.-H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.001 · Cited by 61
Harnessing Extracellular Matrix Biology for Tumor Drug Delivery
Subrahmanyam, N., & Ghandehari, H. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020088 · Cited by 42
Metadata
- Authors
- Kultti, A., Li, X., Jiang, P., Thompson, C. B., Frost, G. I., & Shepard, H. M.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2012-09-06
- Volume
- 4
- Issue
- 3
- Pages
- 873-903
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2089668087
- Cited by
- 105
- References
- 16
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.